Vivek Subbiah: Such a delight to discuss some of the oncology updates at ASCO24 with Chadi Nabhan

Vivek Subbiah shared a post by Chadi Nabhan, Medical Director of The University of Chicago Medical Center, on X:

“Such a delight to discuss some of the cutting-edge oncology updates at ASCO24 with the incredible Chadi Nabhan healthcare unfiltered podcast !

Had a fantastic conversation about my insights on the ASCO 2024 meeting. Shout out to Navneet Majhail in the podcast Can’t wait to share more after ESMO24 and other major meetings. Listen to this and stay tuned for more !”

Quoting Chadi Nabhan‘s post:

“The ASCO24 recently completed W practice-changing data presented. But what were Vivek Subbiah of Sarah Cannon Docs takes on the meeting overall? Vivek joins me on Healthcare Unfiltered to share his observations.

First Episode of ‘VIVEK’s Takes.’”

Source: Vivek Subbiah/X and Chadi Nabhan/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.